EAM Investors’s Inovio Pharmaceuticals INO Stock Holding History

EAM Investors’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-8,728	Closed	-$968K	–	328
2016 Q2	$968K	Sell	8,728 -498	-5%	-$60.5K	0.15%	256
2016 Q1	$964K	Buy	+9,226	New	+$712K	0.15%	247
2014 Q2	–	Sell	-6,323	Closed	-$1.01M	–	340
2014 Q1	$1.01M	Buy	+6,323	New	+$908K	0.18%	295

Other funds holding INO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

EAM Investors's INO Position: Q3 2016 in Review

EAM Investors sold out of Inovio Pharmaceuticals (INO) in Q3 2016, closing a stake of 8,728 shares — an estimated $968K sold.

EAM Investors first reported a position in INO in Q1 2014 and held it in 3 quarters. The position peaked at $1.01M in Q1 2014. 125 funds tracked by Wall St. Rank hold INO as of Q3 2016.

EAM Investors reported no remaining Inovio Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
EAM Investors sold 8,728 Inovio Pharmaceuticals shares in Q3 2016, an estimated $968K.
EAM Investors first reported a position in Inovio Pharmaceuticals in Q1 2014 and held it in 3 quarters.
EAM Investors's Inovio Pharmaceuticals position peaked at $1.01M in Q1 2014.
125 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2016.

Based on EAM Investors's 13F filing for Q3 2016, filed 10 Nov 2016.